These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9795389)

  • 1. Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees.
    Bagarazzi ML; Boyer JD; Ugen KE; Javadian MA; Chattergoon M; Shah A; Bennett M; Ciccarelli R; Carrano R; Coney L; Weiner DB
    Vaccine; 1998 Nov; 16(19):1836-41. PubMed ID: 9795389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids.
    Boyer JD; Cohen AD; Ugen KE; Edgeworth RL; Bennett M; Shah A; Schumann K; Nath B; Javadian A; Bagarazzi ML; Kim J; Weiner DB
    AIDS; 2000 Jul; 14(11):1515-22. PubMed ID: 10983638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial.
    Ugen KE; Boyer JD; Wang B; Bagarazzi M; Javadian A; Frost P; Merva MM; Agadjanyan MG; Nyland S; Williams WV; Coney L; Ciccarelli R; Weiner DB
    Vaccine; 1997 Jun; 15(8):927-30. PubMed ID: 9234550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees.
    Bagarazzi ML; Boyer JD; Javadian MA; Chattergoon M; Dang K; Kim G; Shah J; Wang B; Weiner DB
    J Med Primatol; 1997; 26(1-2):27-33. PubMed ID: 9271186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.
    Boyer JD; Ugen KE; Wang B; Agadjanyan M; Gilbert L; Bagarazzi ML; Chattergoon M; Frost P; Javadian A; Williams WV; Refaeli Y; Ciccarelli RB; McCallus D; Coney L; Weiner DB
    Nat Med; 1997 May; 3(5):526-32. PubMed ID: 9142121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans.
    Ugen KE; Nyland SB; Boyer JD; Vidal C; Lera L; Rasheid S; Chattergoon M; Bagarazzi ML; Ciccarelli R; Higgins T; Baine Y; Ginsberg R; Macgregor RR; Weiner DB
    Vaccine; 1998 Nov; 16(19):1818-21. PubMed ID: 9795386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV gp120 vaccine gene therapy (Wyeth-Lederle Vaccines-Malvern).
    Drugs R D; 1999 Jun; 1(6):448. PubMed ID: 10566079
    [No Abstract]   [Full Text] [Related]  

  • 8. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
    Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
    Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA and other technologies for HIV vaccines.
    Bowers M
    BETA; 1998 Apr; ():9-12, 28. PubMed ID: 11365275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.
    zur Megede J; Otten GR; Doe B; Liu H; Leung L; Ulmer JB; Donnelly JJ; Barnett SW
    J Virol; 2003 Jun; 77(11):6197-207. PubMed ID: 12743276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees.
    Bagarazzi ML; Boyer JD; Javadian MA; Chattergoon MA; Shah AR; Cohen AD; Bennett MK; Ciccarelli RB; Ugen KE; Weiner DB
    J Infect Dis; 1999 Oct; 180(4):1351-5. PubMed ID: 10479171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.
    Muthumani K; Zhang D; Dayes NS; Hwang DS; Calarota SA; Choo AY; Boyer JD; Weiner DB
    Virology; 2003 Sep; 314(1):134-46. PubMed ID: 14517067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
    Akahata W; Yang ZY; Nabel GJ
    J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.
    MacGregor RR; Boyer JD; Ugen KE; Lacy KE; Gluckman SJ; Bagarazzi ML; Chattergoon MA; Baine Y; Higgins TJ; Ciccarelli RB; Coney LR; Ginsberg RS; Weiner DB
    J Infect Dis; 1998 Jul; 178(1):92-100. PubMed ID: 9652427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
    Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
    Gorse GJ; Baden LR; Wecker M; Newman MJ; Ferrari G; Weinhold KJ; Livingston BD; Villafana TL; Li H; Noonan E; Russell ND;
    Vaccine; 2008 Jan; 26(2):215-23. PubMed ID: 18055072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees.
    Boyer JD; Ugen KE; Chattergoon M; Wang B; Shah A; Agadjanyan M; Bagarazzi ML; Javadian A; Carrano R; Coney L; Williams WV; Weiner DB
    J Infect Dis; 1997 Dec; 176(6):1501-9. PubMed ID: 9395361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.